Agency Information Collection Activities; Proposed Collection; Comment Request; Current Good Manufacturing Practice in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements, 40840-40842 [2010-17054]
Download as PDF
40840
Federal Register / Vol. 75, No. 134 / Wednesday, July 14, 2010 / Notices
TABLE 1.—ESTIMATED ANNUAL REPORTING BURDEN1—Continued
21 CFR Section
No of
Recordkeepers
Annual Frequency per
Recordkeeping
Total Annual
Records
Hours Per
Record
Total Hours
120.8(b)(7) and
120.12(a)(4)(i) and (b)
1,450
14,600
21,170,000
120.10(c) and
120.12(a)(4)(ii) and (b)
1,840
12
22,080
0.1
2,208
120.11(a)(1)(iv) and (a)(2)
and 120.12(a)(5)
1,840
52
95,680
0.1
9,568
120.11(b) and 120.12(a)(5)
and (b)
1,840
1
1,840
4
7,360
120.11(c) and 120.12(a)(5)
and (b)
1,840
1
1,840
4
7,360
308
1
308
4
1,232
120.14(a)(2), (c), and (d)
0.01
Total
emcdonald on DSK2BSOYB1PROD with NOTICES
1 There
211,700
358,466
are no capital costs or operating and maintenance costs associated with this collection of information.
Table 1 of this document provides a
breakdown of the total estimated annual
recordkeeping burden. FDA bases this
hour burden estimate on its experience
with the application of HACCP
principles in food processing.
The burden estimates in table 1 of this
document are based on an estimate of
the total number of juice manufacturing
plants (i.e., 2,300) affected by the
regulations. Included in this total are
850 plants currently identified in FDA’s
official establishment inventory plus
1,220 very small apple juice
manufacturers and 230 very small
orange juice manufacturers. The total
burden hours are derived by estimating
the number of plants affected by each
portion of this final rule and
multiplying the corresponding number
by the number of records required
annually and the hours needed to
complete the record. These numbers
were obtained from the agency’s final
regulatory impact analysis prepared for
these regulations.
Moreover, these estimates assume that
every processor will prepare sanitary
standard operating procedures and a
HACCP plan and maintain the
associated monitoring records and that
every importer will require product
safety specifications. In fact, there are
likely to be some small number of juice
processors that, based upon their hazard
analysis, determine that they are not
required to have a HACCP plan under
these regulations.
Dated: July 9, 2010.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2010–17150 Filed 7–13–10; 8:45 am]
BILLING CODE 4160–01–S
VerDate Mar<15>2010
16:07 Jul 13, 2010
Jkt 220001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2010–N–0355]
Agency Information Collection
Activities; Proposed Collection;
Comment Request; Current Good
Manufacturing Practice in
Manufacturing, Packaging, Labeling, or
Holding Operations for Dietary
Supplements
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing an
opportunity for public comment on the
proposed collection of certain
information by the agency. Under the
Paperwork Reduction Act of 1995 (the
PRA), Federal agencies are required to
publish notice in the Federal Register
concerning each proposed collection of
information, including each proposed
extension of an existing collection of
information, and to allow 60 days for
public comment in response to the
notice. This notice solicits comments on
the information collection provisions of
FDA’s regulations regarding current
good manufacturing practice (CGMP) for
dietary supplements.
DATES: Submit either electronic or
written comments on the collection of
information by September 13, 2010.
ADDRESSES: Submit electronic
comments on the collection of
information to https://
www.regulations.gov. Submit written
comments on the collection of
information to the Division of Dockets
PO 00000
Frm 00071
Fmt 4703
Sfmt 4703
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852. All
comments should be identified with the
docket number found in brackets in the
heading of this document.
FOR FURTHER INFORMATION CONTACT:
Denver Presley, Jr., Office of Information
Management, Food and Drug
Administration, 1350 Piccard Dr., PI50–
400B, Rockville, MD 20850, 301–796–
3793.
Under the
PRA (44 U.S.C. 3501–3520), Federal
agencies must obtain approval from the
Office of Management and Budget
(OMB) for each collection of
information they conduct or sponsor.
‘‘Collection of information’’ is defined in
44 U.S.C. 3502(3) and 5 CFR 1320.3(c)
and includes agency requests or
requirements that members of the public
submit reports, keep records, or provide
information to a third party. Section
3506(c)(2)(A) of the PRA (44 U.S.C.
3506(c)(2)(A)) requires Federal agencies
to provide a 60-day notice in the
Federal Register concerning each
proposed collection of information,
including each proposed extension of an
existing collection of information,
before submitting the collection to OMB
for approval. To comply with this
requirement, FDA is publishing notice
of the proposed collection of
information set forth in this document.
With respect to the following
collection of information, FDA invites
comments on these topics: (1) Whether
the proposed collection of information
is necessary for the proper performance
of FDA’s functions, including whether
the information will have practical
utility; (2) the accuracy of FDA’s
SUPPLEMENTARY INFORMATION:
E:\FR\FM\14JYN1.SGM
14JYN1
Federal Register / Vol. 75, No. 134 / Wednesday, July 14, 2010 / Notices
estimate of the burden of the proposed
collection of information, including the
validity of the methodology and
assumptions used; (3) ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques,
when appropriate, and other forms of
information technology.
emcdonald on DSK2BSOYB1PROD with NOTICES
Current Good Manufacturing Practice
in Manufacturing, Packaging, Labeling,
or Holding Operations for Dietary
Supplements—21 CFR Part 111 (OMB
Control Number 0910–0606)—Extension
On October 25, 1994, the Dietary
Supplement Health and Education Act
(DSHEA) (Public Law 103–417) was
signed into law. DSHEA, among other
things, amended the Federal Food,
Drug, and Cosmetic Act (the act) by
adding section 402(g) of the act (21
U.S.C. 342(g)). Section 402(g)(2) of the
act provides, in part, that the Secretary
of Health and Human Services may, by
regulation, prescribe good
manufacturing practices for dietary
supplements. Section 402(g) of the act
also stipulates that such regulations
shall be modeled after CGMP
regulations for food and may not impose
standards for which there are no
current, and generally available,
analytical methodology. Section
402(g)(1) of the act states that a dietary
supplement is adulterated if ‘‘it has been
prepared, packed, or held under
conditions that do not meet current
good manufacturing practice
regulations.’’ Under section 701(a) of the
act (21 U.S.C. 371(a)), FDA may issue
regulations necessary for the efficient
enforcement of the act. In the Federal
Register of June 25, 2007 (72 FR 34752)
(the June 25, 2007, final rule) FDA
published a final rule that established,
in part 111 (21 CFR part 111), the
minimum CGMP necessary for activities
related to manufacturing, packaging,
labeling, or holding dietary supplements
to ensure the quality of the dietary
supplement.
Records are an indispensable
component of CGMP. The records
required by FDA’s regulations in part
111 provide the foundation for the
planning, control, and improvement
processes that constitute a quality
control system. Implementation of these
processes in a manufacturing operation
serves as the backbone to CGMP. The
records will show what is to be
manufactured; what was, in fact,
VerDate Mar<15>2010
16:07 Jul 13, 2010
Jkt 220001
manufactured; and whether the controls
that the manufacturer put in place to
control the identity, purity, strength,
and composition and limits on
contaminants and to prevent
adulteration were effective. Further,
records will show whether and what
deviations from control processes
occurred, facilitate evaluation and
corrective action concerning these
deviations (including, where necessary,
whether associated batches of product
should be recalled from the
marketplace), and enable a
manufacturer to assure that the
corrective action was effective. In
addition, by requiring records, FDA will
be able to ensure that industry follows
CGMP during manufacturing,
packaging, labeling, or holding
operations. The regulations in part 111
establish the minimum manufacturing
practices necessary to ensure that
dietary supplements are manufactured,
packaged, labeled, or held in a manner
that will ensure the quality of the
dietary supplements during
manufacturing, packaging, labeling or
holding operations.
The records requirements of the
regulations include written procedures
and records pertaining to: (1) Personnel;
(2) sanitation; (3) calibration of
instruments and controls; (4)
calibration, inspection, or checks of
automated, mechanical, or electronic
equipment; (5) maintaining, cleaning,
and sanitizing equipment and utensils
and other contact surfaces; (6) water
used that may become a component of
the dietary supplement; (7) production
and process controls; (8) quality control;
(9) components, packaging, labels and
product received for packaging and
labeling; (10) master manufacturing and
batch production; (11) laboratory
operations; (12) manufacturing
operations; (13) packaging and labeling
operations; (14) holding and distributing
operations; (15) returned dietary
supplements; and (16) product
complaints.
Description of Respondents:
Manufacturers, dietary supplement
manufacturers, packagers and
repackagers, labelers and re-labelers,
holders, distributors, warehousers,
exporters, importers, large businesses,
and small businesses.
The recordkeeping requirements of
the regulations in part 111 are set forth
in each subpart. In table 1 of this
document we list the annual burdens
associated with recordkeeping. In the
table, where the same records are
mentioned in more than one provision
PO 00000
Frm 00072
Fmt 4703
Sfmt 4703
40841
of a subpart, we list the burden under
the provisions corresponding to the
heading in the June 25, 2007, final rule,
‘‘Under this subpart, what records must
you make and keep?’’ For some
provisions listed in table 1, we did not
estimate the annual frequency of
recordkeeping because recordkeeping
occasions consist of frequent brief
entries of dates, temperatures,
monitoring results, or documentation
that specific actions were taken.
Information might be recorded a few
times a day, week, or month. When the
records burden involves frequent brief
entries, we entered one as the default for
the annual frequency of recordkeeping.
For example, many of the records listed
under § 111.35 in table 1, such as
§ 111.35(b)(2) (documentation, in
individual equipment logs, of the date
of the use, maintenance, cleaning, and
sanitizing of equipment), involve many
short sporadic entries over the course of
the year, varying across equipment and
plants in the industry. We did not
attempt to estimate the actual number of
recordkeeping occasions for these
provisions, but instead entered an
estimate of the average number of hours
per year. We entered the default value
of 1 as the annual frequency of
recordkeeping for these and similar
provisions. For § 111.35, the entry for
annual frequency is 1 as a default
representing a large number of brief
recordkeeping occasions.
In many rows of table 1 of this
document, we list a burden under a
single provision that covers the written
procedures or records described in
several provisions. For example, the
burden of the batch production records
listed in table 1 under § 111.260
includes the burden for records listed
under § 111.255 because the batch
production records must include those
records.
The annual frequency for batch
production records (and other records
kept on a batch basis in table 1 of this
document) equals the annual number of
batches. The estimated burden for
records kept by batch includes both
records kept for every batch and records
kept for some but not all batches. We
use the annual number of batches as the
frequency for records that will not
necessarily be kept for every batch, such
as test results or material review and
disposition records, because such
records are part of records, if they are
necessary, that will be kept for every
batch.
FDA estimates the burden of this
collection of information as follows:
E:\FR\FM\14JYN1.SGM
14JYN1
40842
Federal Register / Vol. 75, No. 134 / Wednesday, July 14, 2010 / Notices
TABLE 1.—ESTIMATED ANNUAL RECORDKEEPING BURDEN1
21 CFR Section
No. of
Recordkeepers
Annual Frequency
per Recordkeeping
Total Annual
Records
Hours per
Record
Total Hours
111.14
15,000
4
60,000
1
111.23
15,000
1
15,000
0.2
3,000
111.35
400
1
400
12.5
5,000
111.95
250
1
250
45
11,250
111.140
240
1,163
279,120
1
279,120
111.180
240
1,163
279,120
1
279,120
111.210
240
1
240
111.260
145
1,408
204,160
1
204,160
111.325
120
1
120
15
1,800
111.375
260
1
260
2
520
111.430
50
1
50
12.6
630
111.475
15,000
1
15,000
0.4
6,000
111.535
110
4
440
13.5
5,940
111.570
240
600
144,000
0.5
72,000
2.5
Total
emcdonald on DSK2BSOYB1PROD with NOTICES
1 There
60,000
600
929,140
are no capital or operating and maintenance costs associated with this collection of information.
The burden estimates in table 1 of this
document are based on those in the June
25, 2007, final rule, which were based
on our institutional experience with
other CGMP requirements and on data
provided by Research Triangle Institute
in the ‘‘Survey of Manufacturing
Practices in the Dietary Supplement
Industry’’ cited in that rule.
The estimates in table 1 of the number
of firms affected by each provision of
part 111 are based on the percentage of
manufacturers, packagers, labelers,
holders, distributors, and warehousers
that reported in the survey that they
have not established written SOPs or do
not maintain records that were later
required by the June 25, 2007, final rule.
Because we do not have survey results
for general warehouses, we entered the
approximate number of facilities in that
category for those provisions covering
general facilities. For the dietary
supplement industry, the survey
estimated that 1,460 firms would be
covered by the final rule, including
manufacturers, packagers, labelers,
holders, distributors, and warehousers.
The time estimates include the burden
involved in documenting that certain
requirements are performed and in
recordkeeping. We used an estimated
annual batch production of 1,408
batches per year to estimate the burden
of requirements that are related to the
VerDate Mar<15>2010
16:07 Jul 13, 2010
Jkt 220001
number of batches produced annually,
such as § 111.260, ‘‘What must the batch
production record include?’’ The
estimate of 1,408 batches per year is
near the midpoint of the number of
annual batches reported by survey
firms.
The length of time that CGMP records
must be maintained is set forth in
§ 111.605. Table 1 of this document
reflects the estimated burdens for
written procedures, record maintenance,
periodically reviewing records to
determine if they may be discarded, and
for any associated documentation for
that activity for records that are required
under part 111. We have not included
a separate estimate of burden for those
sections that require maintaining
records in accordance with § 111.605,
but have included those burdens under
specific provisions for keeping records.
For example, § 111.255(a) requires that
the batch production records be
prepared every time a batch is
manufactured, and § 111.255(d) requires
that batch production records be kept in
accordance with § 111.605. The
estimated burdens for both § 111.255(a)
and (d) are included under § 111.260
(what the batch record must include).
PO 00000
Frm 00073
Fmt 4703
Sfmt 4703
Dated: July 8, 2010.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2010–17054 Filed 7–13–10; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Public Health Service Act (PHS),
Delegation of Authority
Notice is hereby given that I have
delegated to the Director, Centers for
Disease Control and Prevention, with
authority to redelegate, the authorities
vested in the Secretary of Health and
Human Services under the following
section under Title XXVI of the Public
Health Service Act, and the Ryan White
HIV/AIDS Treatment Extension Act of
2009 (Pub. L. 111–87), as amended
hereafter, as it pertains to the functions
assigned to the Centers for Disease
Control and Prevention:
• Section 2695 (42 U.S.C. 300ff–
131)—Infectious Diseases and
Circumstances Relevant to Notification
Requirements.
These authorities shall be exercised
under the Department’s policy on
regulations and existing delegation of
E:\FR\FM\14JYN1.SGM
14JYN1
Agencies
[Federal Register Volume 75, Number 134 (Wednesday, July 14, 2010)]
[Notices]
[Pages 40840-40842]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-17054]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2010-N-0355]
Agency Information Collection Activities; Proposed Collection;
Comment Request; Current Good Manufacturing Practice in Manufacturing,
Packaging, Labeling, or Holding Operations for Dietary Supplements
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing an
opportunity for public comment on the proposed collection of certain
information by the agency. Under the Paperwork Reduction Act of 1995
(the PRA), Federal agencies are required to publish notice in the
Federal Register concerning each proposed collection of information,
including each proposed extension of an existing collection of
information, and to allow 60 days for public comment in response to the
notice. This notice solicits comments on the information collection
provisions of FDA's regulations regarding current good manufacturing
practice (CGMP) for dietary supplements.
DATES: Submit either electronic or written comments on the collection
of information by September 13, 2010.
ADDRESSES: Submit electronic comments on the collection of information
to https://www.regulations.gov. Submit written comments on the
collection of information to the Division of Dockets Management (HFA-
305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061,
Rockville, MD 20852. All comments should be identified with the docket
number found in brackets in the heading of this document.
FOR FURTHER INFORMATION CONTACT: Denver Presley, Jr., Office of
Information Management, Food and Drug Administration, 1350 Piccard Dr.,
PI50-400B, Rockville, MD 20850, 301-796-3793.
SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501-3520), Federal
agencies must obtain approval from the Office of Management and Budget
(OMB) for each collection of information they conduct or sponsor.
``Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes agency requests or requirements that members of
the public submit reports, keep records, or provide information to a
third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A))
requires Federal agencies to provide a 60-day notice in the Federal
Register concerning each proposed collection of information, including
each proposed extension of an existing collection of information,
before submitting the collection to OMB for approval. To comply with
this requirement, FDA is publishing notice of the proposed collection
of information set forth in this document.
With respect to the following collection of information, FDA
invites comments on these topics: (1) Whether the proposed collection
of information is necessary for the proper performance of FDA's
functions, including whether the information will have practical
utility; (2) the accuracy of FDA's
[[Page 40841]]
estimate of the burden of the proposed collection of information,
including the validity of the methodology and assumptions used; (3)
ways to enhance the quality, utility, and clarity of the information to
be collected; and (4) ways to minimize the burden of the collection of
information on respondents, including through the use of automated
collection techniques, when appropriate, and other forms of information
technology.
Current Good Manufacturing Practice in Manufacturing, Packaging,
Labeling, or Holding Operations for Dietary Supplements--21 CFR Part
111 (OMB Control Number 0910-0606)--Extension
On October 25, 1994, the Dietary Supplement Health and Education
Act (DSHEA) (Public Law 103-417) was signed into law. DSHEA, among
other things, amended the Federal Food, Drug, and Cosmetic Act (the
act) by adding section 402(g) of the act (21 U.S.C. 342(g)). Section
402(g)(2) of the act provides, in part, that the Secretary of Health
and Human Services may, by regulation, prescribe good manufacturing
practices for dietary supplements. Section 402(g) of the act also
stipulates that such regulations shall be modeled after CGMP
regulations for food and may not impose standards for which there are
no current, and generally available, analytical methodology. Section
402(g)(1) of the act states that a dietary supplement is adulterated if
``it has been prepared, packed, or held under conditions that do not
meet current good manufacturing practice regulations.'' Under section
701(a) of the act (21 U.S.C. 371(a)), FDA may issue regulations
necessary for the efficient enforcement of the act. In the Federal
Register of June 25, 2007 (72 FR 34752) (the June 25, 2007, final rule)
FDA published a final rule that established, in part 111 (21 CFR part
111), the minimum CGMP necessary for activities related to
manufacturing, packaging, labeling, or holding dietary supplements to
ensure the quality of the dietary supplement.
Records are an indispensable component of CGMP. The records
required by FDA's regulations in part 111 provide the foundation for
the planning, control, and improvement processes that constitute a
quality control system. Implementation of these processes in a
manufacturing operation serves as the backbone to CGMP. The records
will show what is to be manufactured; what was, in fact, manufactured;
and whether the controls that the manufacturer put in place to control
the identity, purity, strength, and composition and limits on
contaminants and to prevent adulteration were effective. Further,
records will show whether and what deviations from control processes
occurred, facilitate evaluation and corrective action concerning these
deviations (including, where necessary, whether associated batches of
product should be recalled from the marketplace), and enable a
manufacturer to assure that the corrective action was effective. In
addition, by requiring records, FDA will be able to ensure that
industry follows CGMP during manufacturing, packaging, labeling, or
holding operations. The regulations in part 111 establish the minimum
manufacturing practices necessary to ensure that dietary supplements
are manufactured, packaged, labeled, or held in a manner that will
ensure the quality of the dietary supplements during manufacturing,
packaging, labeling or holding operations.
The records requirements of the regulations include written
procedures and records pertaining to: (1) Personnel; (2) sanitation;
(3) calibration of instruments and controls; (4) calibration,
inspection, or checks of automated, mechanical, or electronic
equipment; (5) maintaining, cleaning, and sanitizing equipment and
utensils and other contact surfaces; (6) water used that may become a
component of the dietary supplement; (7) production and process
controls; (8) quality control; (9) components, packaging, labels and
product received for packaging and labeling; (10) master manufacturing
and batch production; (11) laboratory operations; (12) manufacturing
operations; (13) packaging and labeling operations; (14) holding and
distributing operations; (15) returned dietary supplements; and (16)
product complaints.
Description of Respondents: Manufacturers, dietary supplement
manufacturers, packagers and repackagers, labelers and re-labelers,
holders, distributors, warehousers, exporters, importers, large
businesses, and small businesses.
The recordkeeping requirements of the regulations in part 111 are
set forth in each subpart. In table 1 of this document we list the
annual burdens associated with recordkeeping. In the table, where the
same records are mentioned in more than one provision of a subpart, we
list the burden under the provisions corresponding to the heading in
the June 25, 2007, final rule, ``Under this subpart, what records must
you make and keep?'' For some provisions listed in table 1, we did not
estimate the annual frequency of recordkeeping because recordkeeping
occasions consist of frequent brief entries of dates, temperatures,
monitoring results, or documentation that specific actions were taken.
Information might be recorded a few times a day, week, or month. When
the records burden involves frequent brief entries, we entered one as
the default for the annual frequency of recordkeeping. For example,
many of the records listed under Sec. 111.35 in table 1, such as Sec.
111.35(b)(2) (documentation, in individual equipment logs, of the date
of the use, maintenance, cleaning, and sanitizing of equipment),
involve many short sporadic entries over the course of the year,
varying across equipment and plants in the industry. We did not attempt
to estimate the actual number of recordkeeping occasions for these
provisions, but instead entered an estimate of the average number of
hours per year. We entered the default value of 1 as the annual
frequency of recordkeeping for these and similar provisions. For Sec.
111.35, the entry for annual frequency is 1 as a default representing a
large number of brief recordkeeping occasions.
In many rows of table 1 of this document, we list a burden under a
single provision that covers the written procedures or records
described in several provisions. For example, the burden of the batch
production records listed in table 1 under Sec. 111.260 includes the
burden for records listed under Sec. 111.255 because the batch
production records must include those records.
The annual frequency for batch production records (and other
records kept on a batch basis in table 1 of this document) equals the
annual number of batches. The estimated burden for records kept by
batch includes both records kept for every batch and records kept for
some but not all batches. We use the annual number of batches as the
frequency for records that will not necessarily be kept for every
batch, such as test results or material review and disposition records,
because such records are part of records, if they are necessary, that
will be kept for every batch.
FDA estimates the burden of this collection of information as
follows:
[[Page 40842]]
Table 1.--Estimated Annual Recordkeeping Burden\1\
--------------------------------------------------------------------------------------------------------------------------------------------------------
No. of Annual Frequency Total Annual
21 CFR Section Recordkeepers per Recordkeeping Records Hours per Record Total Hours
--------------------------------------------------------------------------------------------------------------------------------------------------------
111.14 15,000 4 60,000 1 60,000
--------------------------------------------------------------------------------------------------------------------------------------------------------
111.23 15,000 1 15,000 0.2 3,000
--------------------------------------------------------------------------------------------------------------------------------------------------------
111.35 400 1 400 12.5 5,000
--------------------------------------------------------------------------------------------------------------------------------------------------------
111.95 250 1 250 45 11,250
--------------------------------------------------------------------------------------------------------------------------------------------------------
111.140 240 1,163 279,120 1 279,120
--------------------------------------------------------------------------------------------------------------------------------------------------------
111.180 240 1,163 279,120 1 279,120
--------------------------------------------------------------------------------------------------------------------------------------------------------
111.210 240 1 240 2.5 600
--------------------------------------------------------------------------------------------------------------------------------------------------------
111.260 145 1,408 204,160 1 204,160
--------------------------------------------------------------------------------------------------------------------------------------------------------
111.325 120 1 120 15 1,800
--------------------------------------------------------------------------------------------------------------------------------------------------------
111.375 260 1 260 2 520
--------------------------------------------------------------------------------------------------------------------------------------------------------
111.430 50 1 50 12.6 630
--------------------------------------------------------------------------------------------------------------------------------------------------------
111.475 15,000 1 15,000 0.4 6,000
--------------------------------------------------------------------------------------------------------------------------------------------------------
111.535 110 4 440 13.5 5,940
--------------------------------------------------------------------------------------------------------------------------------------------------------
111.570 240 600 144,000 0.5 72,000
--------------------------------------------------------------------------------------------------------------------------------------------------------
Total 929,140
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ There are no capital or operating and maintenance costs associated with this collection of information.
The burden estimates in table 1 of this document are based on those
in the June 25, 2007, final rule, which were based on our institutional
experience with other CGMP requirements and on data provided by
Research Triangle Institute in the ``Survey of Manufacturing Practices
in the Dietary Supplement Industry'' cited in that rule.
The estimates in table 1 of the number of firms affected by each
provision of part 111 are based on the percentage of manufacturers,
packagers, labelers, holders, distributors, and warehousers that
reported in the survey that they have not established written SOPs or
do not maintain records that were later required by the June 25, 2007,
final rule. Because we do not have survey results for general
warehouses, we entered the approximate number of facilities in that
category for those provisions covering general facilities. For the
dietary supplement industry, the survey estimated that 1,460 firms
would be covered by the final rule, including manufacturers, packagers,
labelers, holders, distributors, and warehousers. The time estimates
include the burden involved in documenting that certain requirements
are performed and in recordkeeping. We used an estimated annual batch
production of 1,408 batches per year to estimate the burden of
requirements that are related to the number of batches produced
annually, such as Sec. 111.260, ``What must the batch production
record include?'' The estimate of 1,408 batches per year is near the
midpoint of the number of annual batches reported by survey firms.
The length of time that CGMP records must be maintained is set
forth in Sec. 111.605. Table 1 of this document reflects the estimated
burdens for written procedures, record maintenance, periodically
reviewing records to determine if they may be discarded, and for any
associated documentation for that activity for records that are
required under part 111. We have not included a separate estimate of
burden for those sections that require maintaining records in
accordance with Sec. 111.605, but have included those burdens under
specific provisions for keeping records. For example, Sec. 111.255(a)
requires that the batch production records be prepared every time a
batch is manufactured, and Sec. 111.255(d) requires that batch
production records be kept in accordance with Sec. 111.605. The
estimated burdens for both Sec. 111.255(a) and (d) are included under
Sec. 111.260 (what the batch record must include).
Dated: July 8, 2010.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2010-17054 Filed 7-13-10; 8:45 am]
BILLING CODE 4160-01-S